Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Squassante

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Clinical Pharmacokinetics|December 20, 2002
Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteersLucio Da Ros, Lisa Squassante, Stefano Milleri
British Journal of Clinical Pharmacology|October 24, 2002
Correlation and predictive performances of saliva and plasma nicotine concentration on tobacco withdrawal-induced cravingVincenzo Teneggi, Lisa Squassante, Laura Iavarone, et al.
Psychopharmacology|September 15, 2005
Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 hVincenzo Teneggi, Stephen T Tiffany, Lisa Squassante, et al.
Psychopharmacology|October 31, 2002
Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawalVincenzo Teneggi, Stephen T Tiffany, Lisa Squassante, et al.
Sleep|August 2, 2012
The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomniaPaolo Bettica, Lisa Squassante, Stefano Zamuner, et al.
Pharmaceutical Statistics|February 27, 2007
Sample size calculation for the Power Model for dose proportionality studiesVenkat S Sethuraman, Sergei Leonov, Lisa Squassante, et al.
Pharmacology, Biochemistry, and Behavior|January 16, 2004
EEG power spectra and auditory P300 during free smoking and enforced smoking abstinenceVincenzo Teneggi, Lisa Squassante, Stefano Milleri, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 13, 2012
Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomniaPaolo Bettica, Lisa Squassante, John A Groeger, et al.
Journal of Psychopharmacology (Oxford, England)|September 17, 2005
Characterization of a 7% carbon dioxide (CO2) inhalation paradigm to evoke anxiety symptoms in healthy subjectsStefano Zanone Poma, Stefano Milleri, Lisa Squassante, et al.
Expert Opinion on Investigational Drugs|June 28, 2021
Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteersMichael Derks, Sian Lennon-Chrimes, Andreas Guenther, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Clinical Pharmacokinetics|December 20, 2002
Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteersLucio Da Ros, Lisa Squassante, Stefano Milleri
British Journal of Clinical Pharmacology|October 24, 2002
Correlation and predictive performances of saliva and plasma nicotine concentration on tobacco withdrawal-induced cravingVincenzo Teneggi, Lisa Squassante, Laura Iavarone, et al.
Psychopharmacology|September 15, 2005
Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 hVincenzo Teneggi, Stephen T Tiffany, Lisa Squassante, et al.
Psychopharmacology|October 31, 2002
Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawalVincenzo Teneggi, Stephen T Tiffany, Lisa Squassante, et al.
Sleep|August 2, 2012
The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomniaPaolo Bettica, Lisa Squassante, Stefano Zamuner, et al.
Pharmaceutical Statistics|February 27, 2007
Sample size calculation for the Power Model for dose proportionality studiesVenkat S Sethuraman, Sergei Leonov, Lisa Squassante, et al.
Pharmacology, Biochemistry, and Behavior|January 16, 2004
EEG power spectra and auditory P300 during free smoking and enforced smoking abstinenceVincenzo Teneggi, Lisa Squassante, Stefano Milleri, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 13, 2012
Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomniaPaolo Bettica, Lisa Squassante, John A Groeger, et al.
Journal of Psychopharmacology (Oxford, England)|September 17, 2005
Characterization of a 7% carbon dioxide (CO2) inhalation paradigm to evoke anxiety symptoms in healthy subjectsStefano Zanone Poma, Stefano Milleri, Lisa Squassante, et al.
Expert Opinion on Investigational Drugs|June 28, 2021
Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteersMichael Derks, Sian Lennon-Chrimes, Andreas Guenther, et al.
Pageof 3